Peptides for depression: beyond SSRIs

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptides for Depression: Beyond SSRIs Major depressive disorder affects over 280 million people globally, yet nearly one-third of patients do not achieve remission with conventional antidepressant treatments like SSRIs [1]. This significant treatm...

Peptides for Depression: Beyond SSRIs

Major depressive disorder affects over 280 million people globally, yet nearly one-third of patients do not achieve remission with conventional antidepressant treatments like SSRIs [1]. This significant treatment gap highlights the urgent need for novel therapeutic approaches that extend beyond monoamine hypotheses, focusing instead on neuroplasticity, inflammation, and neuroendocrine modulation. Peptides offer a promising avenue by targeting these complex underlying mechanisms.

Traditional antidepressants, primarily selective serotonin reuptake inhibitors (SSRIs), aim to increase serotonin levels in the synaptic cleft. While effective for many, their delayed onset of action, often 4-6 weeks, and significant side effect profiles, including sexual dysfunction, weight gain, and emotional blunting, limit their utility for a substantial portion of the patient population [2]. Peptides, conversely, operate through diverse pathways, influencing neurotransmitter systems, neurotrophic factors, and inflammatory cascades, potentially offering faster relief and a more favorable side effect profile.

One such peptide, Cerebrolysin, a neuropeptide preparation derived from porcine brain, has demonstrated neurotrophic and neuroprotective properties. It contains biologically active peptides that mimic the action of endogenous neurotrophic factors, promoting neuronal survival, stimulating neurogenesis, and enhancing synaptic plasticity [3]. In animal models, Cerebrolysin has shown antidepressant effects by attenuating oxidative stress and inflammation, as well as enhancing neurogenesis [4]. Clinical trials, primarily in neurological conditions, have also noted improvements in mood and depression scores in patients receiving Cerebrolysin [5]. While specific dosing for depression is still under investigation, typical intravenous administration in neurological contexts ranges from 10-50 ml daily for 10-20 days, often followed by maintenance doses.

Another peptide gaining attention is BPC-157, a stable gastric pentadecapeptide. While widely recognized for its regenerative effects on tissues, BPC-157 also exhibits significant central nervous system activity. Research indicates it can modulate serotonergic and dopaminergic systems, which are crucial for mood regulation [6]. Animal studies have shown BPC-157 to counteract symptoms in depression models, including the forced swimming test and chronic unpredictable stress models, suggesting its potential antidepressant effects are linked to its ability to restore neurotransmitter balance and mitigate stress-induced damage [7]. Clinically, BPC-157 is often administered subcutaneously at doses between 200-500 mcg daily, typically for 2-4 weeks, though some protocols may use up to 1,000 mcg daily depending on individual response and condition severity.

Semax, a synthetic analog of adrenocorticotropic hormone (ACTH), is another neuropeptide with documented nootropic and antidepressant properties. It enhances the activity of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), crucial for neuronal health and plasticity [8]. Semax has been shown to improve cognitive function, reduce anxiety, and exert antidepressant effects, particularly in individuals experiencing asthenic and anxiety-depressive disorders [9]. It's typically administered intranasally, with doses ranging from 0.5 mg to 3 mg daily, often in cycles of 5-14 days. You'll find its rapid action and minimal side effects make it an attractive option for acute depressive episodes or as an adjunct to other therapies.

The nuance in utilizing peptides for depression lies in understanding their distinct mechanisms compared to SSRIs. While SSRIs broadly increase serotonin, peptides like Cerebrolysin and Semax directly promote neuroplasticity and neuroprotection, addressing the structural and functional deficits often observed in chronic depression. BPC-157, with its gut-brain axis modulation, offers a unique approach, considering the growing evidence linking gut dysbiosis to mood disorders. It's important to recognize that these peptides are not typically first-line treatments but represent valuable adjunctive or alternative strategies, especially for those who haven't responded to conventional therapies or experience intolerable side effects.

For a patient experiencing persistent depressive symptoms despite adequate SSRI trials, consider exploring adjunctive Semax at 1 mg intranasally twice daily for 10 days, followed by a re-evaluation of mood and cognitive function, particularly noting improvements in energy and concentration. This approach targets neurotrophic pathways, offering a mechanism distinct from serotonin reuptake inhibition.

References

[1] World Health Organization. (2023). Depression. Retrieved from https://www.who.int/news-room/fact-sheets/detail/depression

[2] Krishnadas, R., & Cavanagh, J. (2012). Depression: an inflammatory illness?. Journal of Neurology, Neurosurgery & Psychiatry, 83(5), 495–502.

[3] Muresanu, D. F., et al. (2019). Cerebrolysin in Stroke: A Review of Clinical Evidence. Journal of the Neurological Sciences, 407, 116402.

[4] El-Sayed, E. M., et al. (2021). Anti-depressant effect of cerebrolysin in reserpine-induced depression in rats: Possible role of oxidative stress and neuroinflammation. Archives of Pharmacal Research, 44(1), 101-110.

[5] Muresanu, D. F., et al. (2022). The Effect of Cerebrolysin on Anxiety, Depression, and Cognition in Patients with Traumatic Brain Injury. Experimental and Therapeutic Medicine, 23(6), 406.

[6] Sikiric, P. C., et al. (2016). Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Current Pharmaceutical Design, 22(12), 1612–1621.

[7] Sikiric, P. P., et al. (2000). The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in two models of depression in rats. Journal of Physiology-Paris, 94(4-5), 319–324.

[8] Dolotov, O. V., et al. (2016). Semax and Selank: Peptides with a wide range of neurobiological activities. Journal of Peptide Science, 22(1), 1–10.

[9] Gusev, E. I., et al. (2010). Clinical efficacy of Semax in patients with asthenic and anxiety-depressive disorders. Neuroscience and Behavioral Physiology, 40(7), 711-716.